-
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
04 Aug 2025 12:40 GMT
… -1010 alternating with trabectedin (Yondelis®) in patients … biotechnology company with a proprietary platform for developing targeted biologic drugs … peptides, antibodies and vaccines. Sonnet’s lead … for the treatment of pancreatic cancer. Forward-Looking …
-
What dinosaur fossils could teach us about cancer
16 Jun 2025 16:19 GMT
… diseases like cancer, that affected dinosaurs.
Cancer’s deep … plants or trees. The drug trabectedin, for example, used to … we can identify cancer-suppressing or cancer-promoting proteins in … detail, tracking how cancer mechanisms evolved over millions …
-
The medicines that lie beneath
02 Jun 2025 05:42 GMT
… , marine biotechnologist at the … pharmaceutical company called Burroughs Wellcome funded a clinical trial to evaluate the drug … Drug Administration (FDA) for treating AIDS. Further clinical trials … medication used in the treatment of patients with breast cancer …
-
CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib
22 May 2025 00:26 GMT
… multiple myeloma patients.
Planned trials include phase II… UK-based clinical-stage biotechnology company, for the advancement … a trabectedin generic, from Accord Healthcare, for treatment of … ;CBP Bromodomain Inhibitor CCS1477. Cancer.gov (accessed May 20, …
-
Peritoneal Cancer Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working In The Therapeutics Segment | Delveinsight
21 May 2025 02:35 GMT
… trials, emerging therapies, and leading companies with DelveInsight @ Peritoneal Cancer Treatment Drugs
Peritoneal Cancer Emerging Drugs … its clinical trial for the treatment of peritoneal cancer.
Azenosertib: Zentalis Pharmaceuticals
Azenosertib is …
-
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
29 Apr 2025 12:35 GMT
… , Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to … .03. Drug Combination Strategies for Cancer Treatment
Abstract Number … , Division of Cancer Medicine, The University … Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical …
-
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
17 Apr 2025 12:30 GMT
… , Gemcitabine, Ifosfamide, Trabectedin, or Vincristine to … .03. Drug Combination Strategies for Cancer Treatment
Abstract Number … of Cancer Medicine, MD Anderson Cancer Center
… Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical …
-
Human medicines European public assessment report (EPAR): Yondelis, trabectedin, Date of authorisation: 17/09/2007, Revision: 28, Status: Authorised
03 Apr 2025 16:18 GMT
Yondelis must be given under the supervision of a doctor who is experienced in the use of chemotherapy (medicines to treat cancer). It should only be used by qualified oncologists (cancer specialists) or other health professionals who are specialised in …
-
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
26 Mar 2025 13:05 GMT
… combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types … trials.” The primary outcome measures for the Phase 1 SB101 trial … biotechnology company with a proprietary platform for developing targeted biologic drugs …
-
Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma
25 Mar 2025 00:34 GMT
… ESMO Sarcoma and Rare Cancers Annual Congress.1
The … press-announcements/fda-approves-first-drug-show-survival-benefit- … U.S. FDA approves Yondelis (trabectedin) for the treatment of patients … sarcoma. News release. Janssen Biotech, Inc. October 23, 2015 …
About
© 1995-2025